Form D · Biotechnology
LogicBio Therapeutics, Inc.
Cambridge, MA · CIK 0001664106
Offering snapshot reported Jul 5, 2017 · SEC filing
- Reported sold
- $29.2M Offering amount: $44.9M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 19, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 5, 2017 | Initial | $29,181,271 | No comparison | 9 | SEC filing |
| Jan 21, 2016 | Initial | $3,999,911 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-290024
Source: Form D, filed Jul 5, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Adi Barzel | Director, Executive |
| Leon Chen | Director |
| Frederic Chereau | Director, Executive |
| Erez Chimovits | Director |
| Sofia Ioannidou | Director |
| Tomer Kariv | Director |
| Mark A. Kay | Director |
| Leszek Lisowski | Director, Executive |
| Daniel O'connell | Director |
| Marc Rubenstein | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
700 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139